Net Medical Xpress Showcases New Telemedicine Technology at Tradeshow

ALBUQUERQUE, N.M., April 15, 2013 -- Net Medical Xpress Solutions, Inc., (OTC Bulletin Board NMXS)(OTCQB: NMXS), announced today that it will be showcasing its newest web-based telemedicine technology at the American Telemedicine Association tradeshow in Austin, Texas on May 5-7, 2013.

Net Medical CEO Dick Govatski said, "In May, we are introducing the latest software and hardware technology from our technology infrastructure group. The team will demonstrate our WebRTC (Web Real Time Communications) software for Google, Chrome and Firefox browsers eliminating the need for plug-ins, downloads and other proprietary installs so that video and audio communications can be connected as easily as opening up a browser.

"In addition, we'll show how our Safety Pilot security platform connected to Panasonic high definition video cameras can be accessed by physicians but tightly restricted to those professionals with credentialing privileges at hospitals using the Net Medical Specialists service.

"Our smart phone and tablet technology will feature demonstrations of our FDA 510k cleared PACS system communicating with hospital electronic health record systems using HL7 interfaces. This will provide doctors with improved patient medical information via telemedicine," Govatski said.

The company also is announcing a new program eliminating the need to purchase expensive video/audio equipment. It will begin offering equipment to hospitals at no cost. Net Medical also provides consultative security services for wireless networks using its Medical Xpress vLan products.

About Net Medical Xpress
Net Medical Express is a medical services company that provides clinical and diagnostic programs using advanced telemedicine solutions for hospitals. The company also develops FDA 510k-cleared and all-inclusive PACS products within the preventative, comprehensive, and critical healthcare segments. For more information, visit www.netmedical.com or www.nmxs.com or contact Dick Govatski, president and CEO, at 505-255-1999 or ceo@nmxs.com.

An investment profile on New Mexico Software may be found at http://www.hawkassociates.com/profile/nmxc.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

For more investor-related questions contact Frank Hawkins, Hawk Associates, at 305-451-1888 or Dick Govatski at 505-255-1999 (ceo@nmxs.com).

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the company's Forms 10-K and 10-Q filed with the SEC.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.